Day1 Plenary Session

Day1 Plenary Session

Lecture 1: Propagation of the neurodegenerative process in PD and the Prion-like hypothesisLecture 2: Can the interaction between genetics, environment, and behavior be a key determinant of PD expression

Lecture 3: What epidemiological and preclinical studies teach us about inflammation and PDLecture 4: Developing new treatments founded on the basic science of PD

Special Lecture 1: The Life and Times of James Parkinson

Special Lecture 2: The Glory of Canadian Sciences and Parkinson's Disease

L1 L2 L3 L4 SpL1 SpL2 Mo X X X X Simon X X X Werner X X X X

Lecture 1: The spectrum of non-motor symptoms in PD

Lecture 2: Dementia and psychiatric manifestations in PD

Lecture 3: Contribution of functional neuroimaging to the understanding of non-motor manifestations of PD

Lecture 4: The impact of other medical conditions on the course of PD

Day 2 Plenary Session

L1 L2 L3 L4 JPL Mo X X X X Simon X X Werner X X X X X

WPC James Parkinson Lecture: Past, Present and Future of Parkinson’s Disease

Day 3 Plenary Session

Lecture 1: Cell and gene-based technologies for restorative and neuroprotective therapies

Lecture 2: Exercise, diet, and other lifestyle activities as treatments for Parkinson disease

Lecture 3: Empowered patients and how they can help improve healthcare

Lecture 4: Roles for healthcare professionals: multidisciplinary care for Parkinson disease.

L1 L2 L3 L4 SpL Mo X X X X X Simon X X X Werner X X X

Special Lecture: Living Positively After a Diagnosis of Parkinson's

Parallel Session: New genes and risk factors of PD

Lecture 1: New PD genes and rare variants Lecture 2: Risk factors for sporadic PDLecture 3: Genetics and gene environment interactions

Parallel Session: Protein misfolding as a key pathogenic event

Lecture 1: Alpha-synuclein conformation and neurodegeneration

Lecture 2: Protein misfolding in neurodegenerative diseases

Lecture 3: Link between lysosomal function and neurodegeneration in PD

Parallel Session: Role of functional imaging modalities in the diagnosis and

management of PD

Lecture 1: Structural imaging for PD: MRI and transcranial sonography (TCS)

Lecture 2: Neurochemical imaging

Lecture 3: Functional connectivity

Parallel Session: Non-dopaminergic systems in PD: Anatomy, Biochemistry, and Pathology

Lecture 1: Role of noradrenaline and serotonin systems for the development of non-motor symptoms Lecture 2: Impact of cholinergic dysfunction on the development of non-motor symptoms Lecture 3: Role of non-dopaminergic systems in the development of L-DOPA-induced dyskinesias

Day 1 Parallel Session I


Workshop 1: Why supporting research is crucial: from government to

private funding agencies

Workshop 2: Mitochondrial defect in PD: myth or reality?

Workshop 3: Sexual issues in Parkinson's disease: assessment and intervention

Workshop 4: Quality of life and comfort in the late stages of Parkinson's disease

L1 L2 L3 L1 L2 L3 L1 L2 L3 L1 L2 L3 W1 W2 W3 W4 Mo X Simon X X Werner X X X

Day 1 Parallel Session II

Parallel Session: Quality of life in Parkinson’s disease: several important determinants

Lecture 1: Practical solutions to driving, early job loss, and relationship issues

Lecture 2: Psychological solutions to dealing with pity, dignity, sense of worth and communication

Lecture 3: Physical solutions to coping with pain, motor/non-motor, cognition, mood, and behavior

Parallel Session: How Parkinson’s affects attention and memory

Lecture 1: Memory and attention issues in Parkinson’s disease—clinical characteristics and mechanisms Lecture 2: Clinical Assessment of Cognition in PD

Lecture 3: Practical management of cognitive deficits in Parkinson's disease; what can occupational therapists offer?

Parallel Session: Experimental models of non-motor manifestations of PD

Lecture 1: Animal models of hyper dopaminergic behavior in Parkinson’s disease Lecture 2: Animal models of sleep disorders in Parkinson’s disease

Lecture 3: Animal models of gastrointestinal dysfunction in Parkinson’s disease

Parallel Session: Optogenetic tools to study PD pathophysiology Lecture 1: Optical Neural Engineering

Lecture 2: Regulation of Parkinsonian motor behaviors by optogenetic control of basal ganglia circuitry

Lecture 3: Optical Interrogation of the dopaminergic systems


Workshop 1: Everything you always wanted to know about genetics and that you never dared to ask

Workshop 2: How researchers and people with Parkinson’s can advance clinical trials together

Workshop 3: How drugs make it to your cabinet

Workshop 4: Music, art, creativity and Parkinson's

L1 L2 L3 L1 L2 L3 L1 L2 L3 L1 L2 L3 W1 W2 W3 W4 Mo X X X X Simon X X X X X Werner X X X


Parallel Session: PD or not PD - that is the question: Is it time to redefine/reclassify Parkinson’s disease?

Lecture 1: Current definitions and diagnostic criteria: reasons for redefining the disorder.

Lecture 2: The challenge of "prodromal" Parkinson's disease

Lecture 3: Redefining Parkinson's disease: possible approaches to developing new diagnostic criteria

Parallel Session: Hallucinations and related phenomena in PD

Lecture 1: Prototypical and less common hallucinations

Lecture 2: Where is the nucleus hallucinatorius and how it gets stimulated?

Lecture 3: Management of hallucinations and related symptoms

Parallel Session: Mitochondrial quality control mechanisms

Lecture 1: Mitochondrial quality control- a matter of life and death for neurons

Lecture 2: Mechanisms of mitophagy in Parkinson’s disease

Lecture 3: Mitochondrial remodeling in the control of apoptosis

Parallel Session: Ways for people with Parkinson’s to become empowered

Lecture 1: Why and how people with Parkinson’s need empowerment - Finding your own niche

Lecture 2: Evidence-based self-management practices

Lecture 3: Increasing Parkinson’s advocacy effectiveness with lessons learned from other diseases


Workshop 1: Benefits and risks of genetic testing

Workshop 2: Sleep and fatigue in PD

Workshop 3: Ethical dilemmas posed by new diagnostic and therapeutic technologies

Workshop 4: Tricks of the trade: clever strategies to improve mobility

L1 L2 L3 L1 L2 L3 L1 L2 L3 L1 L2 L3 W1 W2 W3 W4 Mo X X X Simon X X X Werner X X X X


Parallel Session: PD or look-alikes: how to diagnose them and what are their long-term prognoses?

Lecture 1: Drug Induced Parkinsonism

Lecture 2: PD or progressive supranuclear palsy

Lecture 3: PD or Multiple system atrophy

Parallel Session: Clinical trial outcomes—What do they really mean?

Lecture 1: Clinical trial endpoints in PD – What is really meaningful?Lecture 2: The placebo effect: how it complicates clinical trial results

Lecture 3: Slowing clinical progression in PD –can it be proven in clinical trials?

Parallel Session: The search for new delivery methods for drugs

Lecture 1: Improving oral drug delivery in PD – recent advances Lecture 2: Infusion therapies and other non-oral routes of drug delivery

Lecture 3: Delivering therapeutic genes into the brain – a future way of drug delivery? Parallel Session: Is PD an axonopathy?

Lecture 1: Pathological evidence for axonopathy in Parkinson’s disease

Lecture 2: Evidence for synaptic dysfunction in Parkinson’s disease

Lecture 3: Alterations in axonal transport in Parkinson’s disease


Workshop: Choosing a care facility: When is it time? What are the options?

Workshop: Do experimental models of Parkinson’s disease predict treatment outcome?

Workshop: Complementary and integrative medicine

Workshop: Dance and Parkinson’s: Why and How?

L1 L2 L3 L1 L2 L3 L1 L2 L3 L1 L2 L3 W1 W2 W3 W4 Mo X Simon X X X Werner X X X X


Parallel Session: Update on Gaucher and Parkinson's diseases

Lecture 1: What is new about the link between Gaucher mutations and Parkinsonism

Lecture 2: Exploring mechanisms that underlie between mutations in Gaucher disease gene and synucleinopathy risk Lecture 3: How the understanding of Gaucher could lead to new therapies for Parkinson's

Parallel Session: New insights into Parkinson's disease from experimental cell- and gene-based strategies

Lecture 1: Use of human ES and iPS cells for cell replacement in Parkinson´s disease

Lecture 2: Role of Sonic hedgehog in maintaining striatal homeostasis

Lecture 3: Nurr1 as a therapeutic target for neuroprotection and disease modification in PD

Parallel Session: Neurobiology and treatment of dyskinesiasLecture 1: Maladaptive plasticity in L-DOPA-induced dyskinesia: emerging role of serotonin transmission and other presynaptic factorsLecture 2: Pre- and post-synaptic molecular mechanism underlying L-DOPA-induced dyskinesia possible new pharmacological targetsLecture 3: Multiple dopamine-dependent synaptic mechanisms underlying dyskinesia in animal models

Parallel Session: Pathophysiology and management of head drop and bent spine in PD: Are they dystonia or myopathy or both?

Lecture 1: Myopathy causing camptocormia in idiopathic Parkinson's disease Lecture 2: Camptocormia: pathogenesis, classification, and response to therapy

Lecture 3: Dropped head syndrome in Parkinson's disease


Workshop 1: What you need to know about DBS: Selection, side effects, and new device development

Workshop 2: Is PD an accelerated form of aging?

Workshop 3: Pain in PD

Workshop 4: Speech and Parkinson’s

L1 L2 L3 L1 L2 L3 L1 L2 L3 L1 L2 L3 W1 W2 W3 W4 Mo X X X Simon X X Werner X X X


Parallel Session: Freezing and falls

Lecture 1: Freezing- Underlying mechanisms and the role of cueing

Lecture 2: Why do persons with PD fall? Does treatment help to reduce falling?

Lecture 3: The benefits of exercise in reducing falling in PD

Parallel Session: Promising approaches to identify and validate biomarkers

Lecture 1: What are biomarkers and why do we need them?

Lecture 2: Update on unbiased methodologies to identify biomarkers

Lecture 3: Emerging biomarkers

Parallel Session: Drug development challenges: from the pharmaceutical industry, regulatory agencies, and patient protection organizations perspective

Lecture 1: Drug development challenges-Pharmaceutical industry perspective

Lecture 2: Drug development challenges - A regulatory perspective

Lecture 3: Drug development challenges-Patient protection agency perspective

Parallel Session: How should levodopa induced dyskinesia be managed today?

Lecture 1: Recognizing the subtypes and assessing severity of dyskinesia and the clinical impact

Lecture 2: Current management of LID – medical and surgical

Lecture 3: Future Management of LID: What’s in the pipeline?


Workshop 1: The role of people with Parkinson's in the research process: How are they prepared and what can they do?

Workshop 2: Which physical and mental exercises are good for people with Parkinson’s?

Workshop 3: Parkinson's and Mood Changes: Depression, Apathy and Anxiety

L1 L2 L3 L1 L2 L3 L1 L2 L3 L1 L2 L3 W1 W2 W3 Mo X X X X Simon X X Werner X X X X

Documents

Day1 Plenary Session